Imagine if doctors could know exactly if a high-cost cancer drug will work for you before you even take the first dose. Instead of guessing, they take a simple blood sample to check how your immune system's 'switches' are behaving. It's like checking a car's engine diagnostics before committing to an expensive repair to see if the part will actually fix the problem.
Immune Checkpoint Inhibitors (ICIs) are expensive and can cause severe toxicity in 15-60% of patients, yet only 10-50% of patients actually respond to them. There is a critical need to identify responders before treatment starts to avoid waste and patient harm.
The IOpener® diagnostic platform, including an IVDR-registered sample collection kit and a kinase activity profiling test for melanoma and non-small cell lung cancer.
If you are a clinic dealing with the 15-60% severe toxicity rates of ICIs — this project developed the IOpener® platform that predicts response via a blood draw. This allows doctors to avoid ineffective treatments and reduce patient risk.
If you are an insurer dealing with high costs for treatments that only work for 10-50% of patients — this project developed a diagnostic tool that identifies responders. This ensures reimbursement is spent on therapies with a higher probability of success.
If you are a pharma company dealing with unpredictable clinical trial results for ICIs — this project developed a kinase activity profiling tool. This can be used to better select patient cohorts for clinical trials.
The provided project data does not specify the individual price per test, but it mentions that the project is conducting studies on health and economic benefits to support reimbursement by insurers.
Yes, PamGene has implemented logistical workflows for commercialization and developed a sample collection kit registered under IVDR regulations.
The project utilizes PamGene's proprietary microarray-based kinase activity profiling technology. Based on available project data, the IOpener® is a proprietary platform owned by the coordinator.
The IOpener®-Sample Collection Kit has been registered as an in-vitro diagnostic device under the new IVDR regulation.
The project runs from 2023-08-01 to 2025-07-31, with marketing and sales organizations already being prepared for the start of commercialization.
The project is led by a single SME, PamGene International BV, which holds 100% of the industry ratio. This lean structure suggests a fast-track commercialization strategy where the company controls the entire value chain from proprietary technology development to clinical validation and market entry.
Contact PamGene International BV regarding the IOpener platform
Contact us to explore licensing or partnership opportunities with PamGene.
